H.-W. Dehne (ed.); G. Adam (ed.); M. Diekmann (ed.); J. Frahm (ed.); A. Mauler-Machnik (ed.); P. van Halteren (ed.) Springer (2011) Pehmeäkantinen kirja
Peter M.A. Sloot (ed.); David Abramson (ed.); Alexander V. Bogdanov (ed.); Jack J. Dongarra (ed.); Albert Y. Zomaya (ed.) Springer (2003) Pehmeäkantinen kirja
Richard J. Stancliffe (ed.); Jasinta Dewi (ed.); Günter Houdek (ed.); Rebecca G. Martin (ed.); Christopher A. Tout (ed.) American Institute of Physics (2007) Kovakantinen kirja
J A Caballero (ed.); C E Alonso (ed.); M V Andrés (ed.); Francisco Pérez Bernal (ed.); José Enrique García Ramos (ed.) American Institute of Physics (2010) Pehmeäkantinen kirja
Springer Sivumäärä: 682 sivua Asu: Kovakantinen kirja Painos: 6 Julkaisuvuosi: 2024, 30.01.2024 (lisätietoa) Kieli: Englanti
This introductory text explains both the basic science, production, quality, dosage forms, administration, economic and regulatory aspects and the clinical applications of biotechnology-derived pharmaceuticals. It serves as a complete one-stop source for undergraduate/graduate pharmacists and pharmaceutical science students. An additional important audience are pharmaceutical scientists in industry and academia, particularly those who have not received formal training in pharmaceutical biotechnology and are inexperienced in this field. The rapid growth and advances in the field made it necessary to revise this textbook in order to continue providing up-to-date information and introduce readers to cutting edge knowledge and technology of this field. This Sixth Edition completely updates the previous edition and includes additional coverage on new approaches such as oligonucleotides, siRNA, mRNA, gene therapy, cell therapies, monoclonal antibodies and vaccines. With more than 3-million-chapter downloads, the fifth edition of the textbook has achieved widespread distribution as a key educational resource for the field of pharmaceutical biotechnology.
